SN

Smith & Nephew plc

SNNHealthcareNASDAQ

Medical Devices

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot
MA150-9.31%
$31.60

Price below medium-term moving average.

MA200-9.95%
$31.83

Below long-term trend line.

RSI-14neutral
38.8

Balanced. Not overbought, not oversold.

MACDnegative
-0.0705

Histogram negative, downward momentum.

Financials · Annual
Revenue
$6.16B
+6.1% YoY
Net Income
$625.0M
+51.7% YoY
EBITDA
$1.53B
+25.5% YoY
Free Cash Flow
$1.06B

Scan Results

Daily timeframe
DateIndicatorDetails
Aug 24 RSI OversoldRSI 24.8, below 30, stock may be oversold
Aug 22 RSI OversoldRSI 24.8, below 30, stock may be oversold
About Smith & Nephew plc

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company carries a $11.99B market cap, placing it firmly in the large-cap category. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.

Where SNN stands vs its 150-day and 200-day moving averages

As of the August 24, 2026 close, SNN finished 7.99% below its 150-day moving average ($31.80) and 8.59% below its 200-day moving average ($32.01). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is SNN overbought or oversold?

At the August 24, 2026 close, SNN's RSI(14) was 24.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$11.99B
P/E (TTM)19.77
Fwd P/E11.72
EPS$1.45
Beta0.69
52W Change-23.0%
Dividend Yield2.74%
ROE11.8%
Analysis

Smith & Nephew plc carries $3.78B in total debt against $754.0M in cash reserves — debt is roughly 5.0x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $1.06B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 11.8%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $5.21B to $6.16B.

With a beta below 0.7, Smith & Nephew plc typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Smith & Nephew plc and its sector.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms